
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
On June 15, 2026, ICS-LABA — Incyte Corporation (Moderate to Severe Asthma) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -6.0% in the window around the event. It had already run +13.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved -6.0%. Model confidence at the time: 35%.
See the full scored track record